Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain?

Table 4

Prognostic impact of hormone receptor and HER-2 status.

	𝑛	Prognostic impact of hormone receptor status	Prognostic impact of HER-2 status
Claude et al. [5]	120	none	not examined
Bartsch et al. [8]	174	none	none
Le Scodan et al. [6]	117	receptor negative significantly worse	none
Nam et al. [9]	126	receptor negative significantly worse	HER-2 negative significantly worse
Kirsch et al. [10]	95	not examined	HER-2 negative significantly worse^∗
Eichler et al. [11]	83	none	HER-2 negative significantly worse^⋀
Melisko et al. [12]	112	receptor negative significantly worse	none
Harputluoglu et al. [13]	144	none	none
Park et al. [14]	125	none	HER-2 positive significantly worse
Church et al. [15]	86	not examined	HER-2 negative significantly worse^∗
Own contemporary group	32	none	none

⋀80% of HER-2 overexpressing cases received trastuzumab after diagnosis of brain metastases.∗The difference in survival was limited to patients with HER-2 overexpressing cancer treated with trastuzumab after diagnosis of brain metastases.